MAP2K7 and inflammatory bowel disease: It’s worth acknowledging the dichotomous findings regarding the impact on IBD as certain reports suggested RAF/MEK inhibitors to potentially promote IBD in humans and mice (85, 86), while others have indicated that MEK inhibitors hold promise in improving diarrhea and histological scores in a murine colitis model (84), and RAF inhibition has induced clinical remission in CD patients (87).